Search results
Showing 121 to 135 of 687 results for must
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation
Medical technologies evaluation programme process guide (PMG34)
This process guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.